Cargando…
Rapamycin : effectiveness, safety and drug interactions /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Nova Biomedical/Nova Science Publishers, Inc.,
[2012]
|
| Colección: | Pharmacology-research, safety testing, and regulation series.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- ""RAPAMYCIN""; ""EFFECTIVENESS, SAFETYAND DRUG INTERACTIONS""; ""PHARMACOLOGY
- RESEARCH, SAFETYTESTING AND REGULATION""; ""ORGAN TRANSPLANTATIONRESEARCH HORIZONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""mTOR Inhibitors in Chronic LiverDiseases and Cancer""; ""Abstract""; ""1. Introduction""; ""2. mTOR Signaling in the Liver""; ""mTOR Inhibitors""; ""3. mTOR Inhibition in Chronic LiverDiseases""; ""Steatosis and Insulin Resistance""; ""Steatohepatitis and Fibrogenesis""; ""Cirrhosis""
- ""4. Relevance of mTOR Inhibition inHepatocellular Carcinoma""""Conclusions""; ""References""; ""Starvation Profileof mTOR Inhibitors""; ""Abstract""; ""I. Introduction""; ""2. The Safety Profile of mTOR Inhibitors""; ""2.1. Hyperglycemia""; ""2.2. Dyslipidemia""; ""2.3. Asthenia""; ""2.4. Mucositis, Stomatitis and Mouth Sores""; ""2.5. Pulmonary Toxicity""; ""2.6. Skin Toxicity""; ""2.7. Infection and Malignancy""; ""2.8. Bone Marrow Suppression""; ""2.9. Renal Function Abnormalities""; ""3. mTOR Function in Normal CellPhysiology""; ""3.1. Regulation of Growth Factor Signaling""
- ""3.2. Regulation of Cell Growth and Metabolism""""4. mTOR Integrates Energy-SensingPathways""; ""4.1. AKT: The Link betweenMetabolism and Extracellular Signals""; ""4.2. mTOR Controls the Interfacebetween Nutrient Sensing and Metabolism""; ""4.3. AMPK: A Low-Energy Checkpoint""; ""4.4. AMP-Activated Kinase Controls the Metabolic Checkpoint""; ""5. mTOR Toxicity on Signaling Pathways""; ""6. Leptin""; ""7. Body Weight and Feeding""; ""8. Cross-Talk among mTOR/PKA/AMP""; ""Conclusion""; ""References""
- ""Identification of CandidateBiomarkers Predicting Responseto Rapalogs Therapyin Human Cancer""""Abstract""; ""Introduction""; ""Pathway-based Identificationof Predictive Biomarker""; ""Omics-based Identificationof Predictive Biomarker""; ""Conclusion""; ""References""; ""Influence of Everolimus DrugRegime on Blood Cell Subsetsin Kidney Transplant Patients""; ""Abstract""; ""Introduction""; ""Materials and Methods""; ""Blood Leukocyte and LymphocyteSubset Measurement""; ""Results""; ""Discussion""; ""References""
- ""The Emerging Mechanismof Limited Therapeutic Efficacyof Rapamycin for Cancers""""Abstract""; ""Introduction""; ""a) Overview of Rapamycin""; ""b) Overview of the mTOR Signaling Pathway""; ""c) Overview of Limited Clinical Application of Rapamycinand Its Analogs for Cancer""; ""Rapamycin Can Only Partially InhibitmTORC1 Activity""; ""Rapamycin Cannot Inhibit mTORC2Activity upon Acute Treatment""; ""PI3K/Akt Feedback Loop NegativelyRegulates mTORC1 Activity""; ""Conclusions""; ""References""; ""Rapamycin Controls MultipleSignalling Pathways Involvedin Cancer Cell Survival*""; ""Abstract""